|Patients’ conditions||Number of patients||Comparison||Survival||p Value|
|*CR = colorectal; CHT = chemotherapy; combination CHT = 5-FU, leucovorin, and cisplatin; ELF = 5-FU, leucovorin, and etoposide; FLv = 5-FU and leucovorin.|
|†Patients could receive SC.|
|‡Significant only after correction for imbalances in pretreatment characteristics.|
|Advanced CR and stomach cancer refractory to CHT||107||Octreotide† v SC||20 v 11 weeks||<0.0001|
|Metastatic CR cancer that progressed within 6 months of treatment with fluorouracil||279||Irinotecan plus SC v SC||9.2 v 6.5 months||0.0001|
|Previously untreated, inoperable, locally recurrent or metastatic CR cancer||36||Combination CHT plus SC v SC||11 v 5 months||0.006|
|Advanced, surgically incurable stomach cancer||61||ELF or FLv plus SC v SC||8 v 5 months||0.003‡|
Review: chemotherapy plus supportive care improves survival and quality of life in advanced or metastatic gastrointestinal cancer more than supportive care alone
EBN Twitter Journal Club
The club runs like other journal discussion groups, except that the article and questions are posted on this blog and
the discussion about the article happens on Twitter.
How to participate >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.